My morning pick is The Medicines Company MDCO from the Biomedical Sector.
How does this company make money?
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development. Through the acquisition of Targanta Therapeutics Corporation, The Medicines Company’s pipeline also includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic in late-stage development in the United States.
Last five quarters of top and bottom line:
Other key metrics include a price/earnings ratio (ttm) of 10.01 (Non-Gaap), market cap of $1.02 billion, no dividends, current ratio is 3.80, LT debt/equity is 0, cash and short term investments are $307 million to current liabilities of $125 million. (See MDCO Investor Relations). MDCO is currently trading at $18.72 as of yesterday's closing.
Technical Analysis by MorningPick.
MDCO shares traded down 1.00 percent yesterday closing at $18.66. Right now the price is at a critical resistance level of around $19.00. I would wait for the price to breakout but that may be challenging if this market cools off this week and the Euro debt crisis becomes an issue. Trading ranges can include $16.50 to $19, $14.50 to $16.50, $12 to $14.50 and $7 to $12 (not shown). MDCO's current trend has strengthen and will soon teeter on being oversold. Depending on the overall market, MDCO may breakout to $25.00 then retreat and settle around around $22.00 for a month or two. I would wait for confirmation of a breakout, possibly two days of higher highs and higher lows. If the market sours this week then this may pull MDCO's price back with it. Overall, there is tremendous locked in value within The Medicine Company.
How does this company make money?
The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development. Through the acquisition of Targanta Therapeutics Corporation, The Medicines Company’s pipeline also includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic in late-stage development in the United States.
Last five quarters of top and bottom line:
| Sep 2011 | Jun 2011 | Mar 2011 | Dec 2010 | Sep 2010 | |
| Revenue, $M | 121 | 120 | 112 | 120 | 106 |
| Net Income, $M | 73 | 11 | 24 | 59 | 21 |
| Earnings Per Share, $ | 0.12 | 0.21 | 0.45 | 1.09 | 0.40 |
| Dividend, $ | 0 | 0 | 0 | 0 | 0 |
| Shares Outstanding, K | 54,010 | 53,890 | 53,860 | 53,390 | 53,340 |
Other key metrics include a price/earnings ratio (ttm) of 10.01 (Non-Gaap), market cap of $1.02 billion, no dividends, current ratio is 3.80, LT debt/equity is 0, cash and short term investments are $307 million to current liabilities of $125 million. (See MDCO Investor Relations). MDCO is currently trading at $18.72 as of yesterday's closing.
Technical Analysis by MorningPick.
0 Comment on Post:
Post a Comment